Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: LT who wrote (4938)	3/10/1999 2:09:00 PM
From: r. c. cummings	Read Replies (2) \| Respond to of 5736

This is an old story, and I wouldn't say huge competition, by any means. While the SPRX device probably is applicable for certain preliminary testing, once an infant is suspected of having jaundice and begins phototherapy treatment, the SPRX device no longer works effectively. A hospital then would have to begin heel pricks again to do monitoring during phototherapy. Whereas if the hospital has the CCSI device they can use it for initial diagnosis AND monitoring during treatment. I would bet that hospitals will opt for a single device (CCSI's) that can be used throughout the entire range of diagnosis, treatment, and follow-up monitoring.